Clinical trials have extended beyond two years, and the safety profile appears acceptable for ongoing use
Novo Nordisks semaglutide franchise alone generated approximately $33 billion in 2025, while Eli Lillys tirzepatide continues to capture significant market share
The version that has lost its patent is Victoza, which is approved for diabetes and packaged as an injection pen that is prefilled with the antidiabetic doses (0.6, 1.2, and 1.8 mg), which are lower than the typical antiobesity doses
NTD: Investigation, Methodology, Writing review & editing
Permanent Nature: Unlike medication, which must be taken continuously, surgery is a one-time procedure
chronic sleep deprivation and high oxidative stress deplete reserves